This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
NCT03449381
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
266
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
BI 907828
Sponsor
Boehringer Ingelheim